Progression of macular atrophy on long-term anti-VEGF therapy for AMD
3 October 2022
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Anti-VEGF therapy, Long term, Macular atrophy, neovascular age-related macular degeneration
This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...
Imaging findings for macular dysplasia in nystagmus
4 August 2021
| Fiona Rowe (Prof)
|
Paediatric Ophthalmology / Strabismus
|
Macular dysplasia, SD-OCT, congenital aniridia, foveal hypoplasia, nystagmus, oculocutaneous albinism
This paper reports the retrospective analysis of congenital macular dysplasia in patients with albinism, macular heterotopias, congenital aniridia, foveal hypoplasia, congenital macular coloboma and congenital retinoschisis. The study included 29 eyes of 17 patients. The authors report SD-OCT aids diagnosis...
Conversion factors for fovea on / off detachments
This is a retrospective study of medical records in a single unit over a 14 year period from January 2001 – December 2014, of patients who converted from fovea-on to fovea-off rhegmatogenous retinal detachment (RRD). Ten cases were identified while...
Using OCT to screen and monitor Alzheimer’s disease
1 June 2016
| Claire Howard
|
EYE - Neuro-ophthalmology
|
Macular thickness, mild cognitive impairment, optical coherence tomography, subjective memory complaints
Alzheimer’s disease (AD) is a neurodegenerative illness characterised by progressive decline in cognitive function. AD is the main cause of dementia worldwide. Over recent years researchers have strived to find biomarkers to diagnose AD, particularly in the early stages of...
Intravitreal bevacizumab vs. ranibizumab in the treatment of macular oedema due to BRVO
This is a randomised, prospective, non-inferiority trial of 75 patients with macular oedema due to a branch retinal vein occlusion (BRVO) who received intravitreal injections of ranibizumab or bevacizumab after 1:1 block randomisation. This study is to measure the difference...
